Concurrent combination of high dose imatinib and dose-intensive chemotherapy for patients with newly diagnosed Philadelphia-positive acute lymphoblastic leukemia: Promising preliminary results of JALSG Ph+ALL202 study

6538 Background: Adult patients with Ph+ALL have an extremely poor outcome. In order to improve outcome of patients with Ph+ALL, a phase II trial of high-dose imatinib and dose-intensive chemotherapy was conducted in newly diagnosed Ph+ALL. Methods: In induction therapy, oral imatinib 600 mg/day was given from day 8 for 8 weeks (day 63) with dose-intensive chemotherapy consisting of cyclophosphamide (day 1:i.v. 1200 mg/M2), daunorubicin (days 1–3:i.v. 60 mg/M2), vincristine(days 1,8,15,22: i.v.1.3 mg/M2), prednisolone(days 1–21:p.o. 60 mg/M2). As consolidation therapy, alternating chemotherapy course [high dose chemotherapy with methotrexate(MTX) (day 1: i.v.1 g/M2) and cytarabine (Ara-C)(days 2 and 3:i.v. 2 g/M2 /q12h)] and single administration of oral imatinib (600 mg/day for 4 weeks) were repeated in a total of 8 courses. Risk-adapted intrathecal prophylaxis (MTX+ Ara-C+ dexamethasone) was given. Patients having either related or unrelated HLA-identical donor were permitted to receive allogeneic stem ...